Multitherapy for diabetes.
作者信息
Vos Eddie
出版信息
CMAJ. 2006 Nov 7;175(10):1246-7; author reply 1247. doi: 10.1503/cmaj.1060019.
Abstract
摘要
相似文献
1
Multitherapy for diabetes.糖尿病的多药治疗
CMAJ. 2006 Nov 7;175(10):1246-7; author reply 1247. doi: 10.1503/cmaj.1060019.
2
Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.2型糖尿病治疗与大血管并发症——脂肪和糖形成了危险的“蛋奶酥”。
Metab Syndr Relat Disord. 2009 Apr;7(2):79-81. doi: 10.1089/met.2008.0092.
3
4
Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.索尔维致力于满足患有心脏代谢和脂质紊乱的高血压患者在管理方面未得到满足的需求。
Cardiovasc J Afr. 2009 Jan-Feb;20(1):73-4.
5
[On behalf and the extent of evidence].[代表及依据证据范围]
Rev Med Suisse. 2010 Jun 9;6(252):1171-2.
6
Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.非诺贝特有望从对其活性代谢物非诺贝酸的新研究中获益。
Cardiovasc J Afr. 2008 May-Jun;19(3):171-2.
7
Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.400毫克苯扎贝特对糖尿病合并高脂血症患者的疗效及耐受性
Acta Physiol Hung. 1996;84(4):433-5.
8
Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.近期脂质试验对降低2型糖尿病患者风险的临床意义。
Am J Cardiol. 2007 Feb 19;99(4A):133B-140B. doi: 10.1016/j.amjcard.2006.11.014. Epub 2006 Dec 28.
9
[Atherogenic dyslipidaemia in type 2 diabetes].2型糖尿病中的致动脉粥样硬化性血脂异常
Kardiol Pol. 2006 Oct;64(10 Suppl 6):S567-71.
10
ACCORD and Risk-Factor Control in Type 2 Diabetes.2型糖尿病中的ACCORD研究与危险因素控制
N Engl J Med. 2010 Apr 29;362(17):1628-30. doi: 10.1056/NEJMe1002498. Epub 2010 Mar 14.
本文引用的文献
1
Can diabetes management programs create sustained improvements in disease outcomes?糖尿病管理项目能否持续改善疾病预后？
CMAJ. 2005 Dec 6;173(12):1467-8. doi: 10.1503/cmaj.051343.
2
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.长期非诺贝特治疗对9795例2型糖尿病患者心血管事件的影响（FIELD研究）：随机对照试验
Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.
3
Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.强化多药联合治疗对2型糖尿病患者的疗效：一项随机对照试验。
CMAJ. 2005 Dec 6;173(12):1457-66. doi: 10.1503/cmaj.050054. Epub 2005 Nov 17.
4
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).中度高胆固醇血症高血压患者随机接受普伐他汀与常规治疗的主要结局：预防心脏病发作的抗高血压和降脂治疗试验（ALLHAT-LLT）
JAMA. 2002 Dec 18;288(23):2998-3007. doi: 10.1001/jama.288.23.2998.
5
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.通过提高高密度脂蛋白胆固醇水平和降低冠状动脉疾病患者的甘油三酯水平进行二级预防。
Circulation. 2000 Jul 4;102(1):21-7. doi: 10.1161/01.cir.102.1.21.
6
The Helsinki Heart Study: an 8.5-year safety and mortality follow-up.赫尔辛基心脏研究：8.5年安全性和死亡率随访
J Intern Med. 1994 Jan;235(1):31-9. doi: 10.1111/j.1365-2796.1994.tb01029.x.
Zotero 插件